aMoon Growth Fund Limited Partnership and related reporting persons filed Amendment No. 2 to Schedule 13D with the SEC on November 12, 2026, disclosing beneficial ownership of ordinary shares of SOPHiA GENETICS SA as of an event date of November 10, 2026.
Key Highlights
- Aggregate beneficial ownership: aMoon Growth Fund Limited Partnership and certain affiliated reporting persons each reported 5,318,023 ordinary shares of SOPHiA GENETICS SA beneficially owned.
- Percentage of class: The 5,318,023 shares represent 6.2% of the class, calculated on a base of 85,658,321 ordinary shares outstanding (excluding treasury shares) as of September 30, 2026.
- Voting and dispositive power: Each of the principal reporting persons reported 0 shares with sole voting or sole dispositive power, and 5,318,023 shares with shared voting and shared dispositive power.
- Zero-ownership entities: aMoon Edge Limited Partnership, aMoon Edge GP Ltd., Hilliyon Holdings Ltd., and Berko Capital Ltd. each reported 0 shares beneficially owned, representing 0% of the class.
- Individual reporting person: Yair Chaim Schindel, an Israeli individual, is listed as a reporting person with the same 5,318,023 shares in shared voting and dispositive power, representing 6.2%.
- Event date: The event that required filing of this amendment occurred on November 10, 2026.
- Share par value: The securities covered are ordinary shares of SOPHiA GENETICS SA with a par value of CHF 0.05 per share, CUSIP H82027105.
aMoon Growth Fund and Affiliates Disclose 5,318,023 Shares in SOPHiA GENETICS Amendment
According to Amendment No. 2 to Schedule 13D filed November 12, 2026, aMoon Growth Fund Limited Partnership, organized in the Cayman Islands, reported beneficial ownership of 5,318,023 ordinary shares of SOPHiA GENETICS SA. The filing also names aMoon Growth Fund G.P. Limited Partnership (organized in Israel), aMoon General Partner Ltd. (Israel), and individual reporting person Yair Chaim Schindel (Israel) as holding the same aggregate position of 5,318,023 shares, each with shared voting power and shared dispositive power over all such shares, and no sole voting or dispositive power over any shares.
The filing states that the 6.2% figure is calculated based on a total of 85,658,321 ordinary shares outstanding, excluding treasury shares, as of September 30, 2026, as reported by SOPHiA GENETICS SA in a Form 6-K filed with the SEC on November 3, 2026. The source of funds for aMoon Growth Fund Limited Partnership is listed as working capital ("WC"), while Schindel and aMoon General Partner Ltd. list "OO" (other) as their source of funds.
Four additional entities, specifically aMoon Edge Limited Partnership, aMoon Edge GP Ltd., Hilliyon Holdings Ltd., and Berko Capital Ltd., are named as reporting persons but each reported zero shares beneficially owned and 0% of the class. These entities reported no sole or shared voting or dispositive power over any shares of SOPHiA GENETICS SA. The filing is identified as Amendment No. 2 to the Schedule 13D, with the triggering event dated November 10, 2026.
What Was Disclosed
Amendment No. 2 to Schedule 13D disclosed that aMoon Growth Fund Limited Partnership and affiliated reporting persons, including individual Yair Chaim Schindel, collectively hold shared beneficial ownership of 5,318,023 ordinary shares of SOPHiA GENETICS SA, equal to 6.2% of the outstanding class as of September 30, 2026.




Please wait processing your request...